Journals / Cukurova Medical Journal / 2022 / Cilt: 47 - Sayı: 3

Relationship between disease severity and prognostic indicators and matrix metallaproteinase in patients with stable idiopatic pulmonary fibrosis

Stabil idiyopatik pulmoner fibrozde hastalik şiddeti ve prognostik belirteçler ile matriks metallaproteinaz düzeyleri arasindaki ilişki

Pages
1273–1280
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, because they could open the door to a cutting-edge treatment strategy, these indicators should be investigated prospectively in larger series.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Blood-derived biomarkers have been extensively considered as possible prognostic indicators in idiopathic pulmonary fibrosis (IPF) recently.
📊
Key Findings & Data:Materials and Methods: The study comprised 22 people with an IPF diagnosis that had been verified by a multidisciplinary approach.
💡
Conclusion & Impact:However, because they could open the door to a cutting-edge treatment strategy, these indicators should be investigated prospectively in larger series.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Blood-derived biomarkers have been extensively considered as possible prognostic indicators in idiopathic pulmonary fibrosis (IPF) recently. In order to assess the value of circulating biomarkers in common IPF clinical practice, the study intends to draw conclusions regarding the link between disease severity, prognostic indicators, and serum matrix metalloproteinase in patients with stable idiopathic pulmonary fibrosis. Materials and Methods: The study comprised 22 people with an IPF diagnosis that had been verified by a multidisciplinary approach. The sociodemographic details, clinical and radiologic symptoms, pulmonary function tests and the Gender-Age-Physiology (GAP) score were noted. ELISA has been used to research serum MMP concentrations. Results: There is no statistically significant correlation between the Matrix Metalloproteinase (MMP) 2, MMP 7, MMP 9, and MMP13 and the GAP index and, pulmonary function tests, or disease severity. GAP score was found to be higher in stage 3 in patients with severe disease, in stage 2 in patients with moderate disease, and in stage 1 in patients with mild disease. Conclusion: There are consistent findings in the literature, despite the fact that the association between MMP and IPF prognostic markers, pulmonary function tests, and disease severity could not be seen in this investigation. However, because they could open the door to a cutting-edge treatment strategy, these indicators should be investigated prospectively in larger series.

Özet

Amaç: Biyobelirteçler, son zamanlarda idiyopatik pulmoner fibrozis (İPF) olası tanısında prognostik göstergeler olarak kapsamlı bir şekilde değerlendirilmektedir. Yaygın IPF klinik uygulamasında dolaşımdaki biyobelirteçlerin değerini belirleyebilmek için bu çalışma, stabil idiyopatik pulmoner fibrozlu hastalarda hastalık şiddeti, prognostik göstergeler ve serum matriks metalloproteinaz arasındaki bağlantıya ilişkin sonuçlar çıkarmayı amaçlamaktadır. Gereç ve Yöntem: Çalışma, multidisipliner bir yaklaşımla doğrulanmış İPF tanısı olan 22 kişiden oluşuyordu. Sosyodemografik detaylar, klinik ve radyolojik semptomlar, solunum fonksiyon testleri ve GAP skoru kaydedildi. Serum MMP konsantrasyonları ELISA yöntemiyle ölçülmüştür. Bulgular: Matriks Metalloproteinaz (MMP) 2, MMP 7, MMP 9 ve MMP13 ile GAP indeksi ve solunum fonksiyon testleri veya hastalık şiddeti arasında istatistiksel olarak anlamlı bir ilişki yoktur. GAP skoru ağır hastalığı olanlarda evre 3'te, orta hastalığı olanlarda evre 2'de, hafif hastalığı olanlarda evre 1'de daha yüksek bulundu. Sonuç: MMP ile İPF prognostik belirteçleri, solunum fonksiyon testleri ve hastalık şiddeti arasındaki ilişki bu incelemede görülmemesine rağmen literatürde tutarlı bulgular mevcuttur. Ancak, son teknoloji bir tedavi stratejisine kapı açabilecekleri için, bu göstergeler daha geniş serilerde ileriye dönük olarak araştırılmalıdır.

🔖

Cite This Article

TOPRAK, O. B., ÖZYILMAZ, E., SAYGIDEĞER, Y., GÜZEL, E. (2022). Relationship between disease severity and prognostic indicators and matrix metallaproteinase in patients with stable idiopatic pulmonary fibrosis. Cukurova Medical Journal, Cilt: 47 - Sayı: 3, 1273–1280. https://ajindex.com/articles/476763

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824
  2. Devaraj A. Imaging: how to recognise idiopathic pulmonary fibrosis. Eur Respir Rev. 2014;23:215-9
  3. European Commission. Radiation Protection 118: Referral Guidelines for Imaging. Luxembourg: Office for Official Publications of the European Communities; 2001. Available from: https://health.gov.mt/ en/forms/Documents/radiation_protection.pdf. Accessed August 1, 2017
  4. Thannickal VJ, Murthy M, Balch WE, Chandel NS, Meiners S, Eickelberg O et al. Blue journal conference. Aging and susceptibility to lung disease. Am J Respir Crit Care Med. 2015;191:261-9
  5. Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med. 2014;189:1161-72
  6. Mahalanobish S, Saha S, Dutta S, Sil PC. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis. Pharmacol Res. 2020;152:104591
  7. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697-722
  8. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138-153
  9. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ et al.American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:44- e68
  10. Ranu H, Wilde M, Madden B. Pulmonary function tests. Ulster Med J. 2011;80:84-90
  11. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019 15;200:e70-e88
  12. Liu YM, Nepali K, Liou JP. Idiopathic pulmonary fibrosis: Current status, recent progress, and emerging targets. J Med Chem. 2017;60:527-553
  13. Chambers RC, Mercer PF. Mechanisms of alveolar epithelial inju